NMD Pharma A/S: Financial statements 2020
CVR: 36899069
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -7,870,124 and a net result of EUR -9,928,027 compared with EUR -8,501,273 the year before. Equity in the 2020 report amounted to EUR 9,243,117. The solvency ratio was 80.5%. The company had 22 employees in the financial year.
- Gross Profit
- EUR -7,870,124
- Profit/Loss
- EUR -9,928,027
- Equity
- EUR 9,243,117
- Total Assets
- EUR 11,488,549
- Employees
- 22
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -7.9 mio. EUR | -9.9 mio. EUR | 9.2 mio. EUR | 22 |
| 2019 | - | -7.1 mio. EUR | -8.5 mio. EUR | 140 t. EUR | 17 |
| 2018 | - | -4.7 mio. EUR | -5.5 mio. EUR | 88 t. EUR | 14 |
| 2017 | - | -17.9 mio. | -21.9 mio. | -8.7 mio. | 13 |
| 2016 | - | -6.4 mio. | -6.9 mio. | 13.1 mio. | 5 |
Official annual report
How creditworthy is NMD Pharma A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of June 8, 2020, Monique Claude Schiersing has joined the board of directors of NMD Pharma A/S.
NMD Pharma A/S has published its annual report for 2019. Gross profit came to DKK -7,132,039, and the net result was DKK -8,501,273.
As of April 23, 2020, Roel Bulthuis has joined the board of directors of NMD Pharma A/S.
As of April 23, 2020, Anja Ulrike DR Harmeier has left the board of directors of NMD Pharma A/S.
As of April 23, 2020, Fiona MacLaughlin has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.